Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions ...

A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic prostate cancer.